TITLE

Clinicopathologic characteristics and survival of male breast cancer

AUTHOR(S)
Liu, Dongying; Xie, Guangru; Chen, Ming
PUB. DATE
April 2014
SOURCE
International Journal of Clinical Oncology;Apr2014, Vol. 19 Issue 2, p280
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Backgrounds: Male breast cancer (MBC) is a rare disease and accounts for <1 % of all breast cancers. Methods: We retrospectively analyzed clinicopathologic characteristics and prognosis of MBC patients who were diagnosed in our hospital between March 2002 and March 2012. Results: The median age of diagnosis of MBC was 62 years, which was 9 years older than female breast cancer (FBC) patients. The highest proportion of MBC patients was in the 50-59-year age group. The percentage of invasive ductal carcinoma in MBC was much higher than in FBC ( P = 0.000). The positive rate of estrogen receptors in MBC patients (87.9 %) was significantly higher than in FBC patients ( P = 0.048), whereas HER-2 was positive in 17.2 % of MBC patients, which was significantly lower than in FBC patients ( P = 0.001). There was a consistent significant difference in luminal subtypes of FBC and MBC patients ( P = 0.000). The overall survival rates of MBC were significantly higher than FBC ( P = 0.004). HER-2-positive patients had a statistically worse prognosis than HER-2-negative patients ( P = 0.040). Lymph node metastasis and larger tumor size were also associated with poorer prognosis ( P = 0.056 and P = 0.088). The level of hormones was examined in 7 patients, and abnormal hormone levels were detected in 4. Conclusion: The FBC patients were significantly different from the MBC in clinicopathologic and prognostic characteristics. HER-2 positivity was an important factor for prognosis.
ACCESSION #
95594034

 

Related Articles

  • Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Rakha, E A; Tan, P H; Varga, Z; Tse, G M; Shaaban, A M; Climent, F; van Deurzen, C H M; Purnell, D; Dodwell, D; Chan, T; Ellis, I O // British Journal of Cancer;1/20/2015, Vol. 112 Issue 2, p283 

    Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small...

  • Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Masubuchi, Tatsuo; Tada, Yuichiro; Maruya, Shin-ichiro; Osamura, Yoshiyuki; Kamata, Shin-etsu; Miura, Kouki; Fushimi, Chihiro; Takahashi, Hideaki; Kawakita, Daisuke; Kishimoto, Seiji; Nagao, Toshitaka // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p35 

    Background: Salivary duct carcinoma (SDC) is a highly aggressive disease which often metastasizes to distant sites, and there is no established standard therapy for this systemic disease. Given that SDC is biologically similar to breast and prostate cancer, anti-androgenic receptor (AR) and...

  • Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis. TAIYAN GUO; BOYUAN WANG; YINGZE HUANG; SHUTING JIA; WENRU TANG; YING LUO; YONGYONG REN // Molecular & Clinical Oncology;Nov/Dec2015, Vol. 3 Issue 6, p1353 

    Aberrant methylation of the breast cancer susceptibility gene 1 (BRCA1) promoter is a mechanism for its functional inactivation. It may potentially be used as a prognostic marker in studies for patients with breast cancer and plays an important role in tumorigenesis. Numerous studies have...

  • Squamous cell carcinoma of the breast: particularity and clinical management. Xiao-Le Chen; Jie Luo; Fa-Liang Xu // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 7, p14167 

    Objective: The clinical behavior and prognosis of breast squamous cell carcinoma (SCC) have not been fully characterized; this study aimed to further explore these issues. Methods: Twenty-three patients were identified as having primary SCC (PSCC) or metaplastic SCC (MSCC). Their...

  • Burden of HER2+ metastatic breast cancer substantial.  // PharmacoEconomics & Outcomes News;May2015, Vol. 727 Issue 1, p8 

    The article discusses research being done on the economic burden of human epithelial growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer, which references a study by N. Meyer et al. published in the April 28, 2015 issue of "Cost Effectiveness and Resource Allocation."

  • Clinicopathological characteristics and prognosis of mucinous breast carcinoma. Zhang, Ming; Teng, Xiao-dan; Guo, Xin-xin; Zhao, Ji-shuang; Li, Zhi-gao // Journal of Cancer Research & Clinical Oncology;Feb2014, Vol. 140 Issue 2, p265 

    Purpose: The clinical features and prognosis of mucinous breast carcinoma (MBC) are unclear because of its rarity. The aim was to describe the clinicopathological features and prognosis of patients with MBC in comparison with nonmucinous breast carcinoma (NMBC). Furthermore, we described the...

  • Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. Wishart, Gordon C.; Rakha, Emad; Green, Andrew; Ellis, Ian; Ali, Hamid R.; Provenzano, Elena; Blows, Fiona M.; Caldas, Carlos; Pharoah, Paul D. P. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background PREDICT (www.predict.nhs.uk) is a prognostication and treatment benefit tool for early breast cancer (EBC). The aim of this study was to incorporate the prognostic effect of KI67 status in a new version (v3), and compare performance with the Predict model that includes HER2 status...

  • Clinicopathological study of centrally necrotizing carcinoma of the breast. Yanling Zhang; Yurong Ou; Donghong Yu; Xiang Yong; Xiaoli Wang; Bo Zhu; Qiong Zhang; Lei Zhou; Zhaogen Cai; Zenong Cheng // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Centrally necrotizing carcinoma of the breast (CNC) represents a newly-identified subset of breast cancer. The clinical and pathological characteristics of this breast cancer subtype are not yet completely understood. Methods: We assessed the clinicopathological characteristics of 73...

  • High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. Jacot, William; Mollevi, Caroline; Fina, Frédéric; Lopez-Crapez, Evelyne; Martin, Pierre-Marie; Colombo, Pierre-Emmanuel; Bibeau, Frédéric; Romieu, Gilles; Lamy, Pierre-Jean // BMC Cancer;12/18/2015, Vol. 15, p1 

    Background: Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better understanding of its biology could allow the rational development of targeted therapies.Methods: We extensively analyzed the EGFR/PI3K/PTEN axis in a large,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics